

Curriculum Vitae

IVAN GENTILE

Il Prof. Ivan Gentile si è laureato nel 1996 in Medicina e Chirurgia presso la allora "Seconda Università di Napoli" con votazione di 110/110 con lode. Dal febbraio 1999 al giugno 1999 ha frequentato l'Istituto di Patologia di Colonia (Germania). Nel 2000 si è specializzato in Malattie Infettive all'Università di Napoli "Federico II" con il massimo dei voti (70/70 e lode).

Dal gennaio 2001 al novembre 2007 ha lavorato in qualità di medico presso l'Unità Operativa di Malattie Infettive dell'Azienda Ospedaliera "Federico II". Nell'anno accademico 2011/2012 è stato nominato Ricercatore di Malattie Infettive presso l'Università degli Studi di Napoli "Federico II". Nell'anno accademico 2017/2018 è stato nominato Professore Associato di Malattie infettive dell'Università di Napoli "Federico II".

Ha ideato, realizzato e partecipato a numerosi studi clinici, tra cui RCT.

È autore di circa 140 articoli pubblicati su riviste peer-reviewed con un Impact Factor complessivo di oltre 300. Il numero totale di citazioni corrisponde a 1964 con un H – index di 27 (fonte: Scopus). È anche autore di 5 capitoli di libri. Ha coordinato la stesura e realizzazione di 2 libri di malattie infettive. Tiene relazioni sulle malattie infettive nei principali meeting scientifici nazionali ed internazionali.

Guest Referee per riviste come *Lancet Infectious Diseases*, *Gut*, *Database Cochrane of Systematic Reviews*, *Liver International*, *Journal of Infection*, *Drug Design, Development and Therapy*, *Journal of Translational Medicine*, *Expert Review of Anti-Infective Therapy*, *BMC BMC Infectious Diseases*, *Expert Opinion On Drug Metabolism & Toxicology*, *Hepatology International*, e *World Journal of Gastroenterology*.

Reviewer per il finanziamento di progetti di ricerca per il "UK Medical Research Council" nel 2014, per il "Dutch Health Care Research Organization" nel 2015 e per "Agency for Health Quality and Assessment" in Spagna in occasione della 26a Maratona TV3 sulle malattie infettive nel 2018.

Nel 2013, 2015 e 2016 ha ricevuto finanziamenti nell'ambito del "Fellowship Program" come "Principal Investigator" di progetti riguardanti le epatiti virali.

Publicazioni rilevanti

1. Fortunato G., Castaldo G., Oriani G., Cerini R., Intrieri M., Molinaro E., **Gentile I.**, Borgia G., Piazza M., Salvatore F. and Sacchetti L. Multivariate Discriminant Function based on six biochemical Markers in blood can predict the cirrhotic evolution of chronic hepatitis. *Clinical Chemistry* 2001; 47: 1696-1700 (I.F. 2017: 8,636).
2. **Gentile I.**, Viola C., Reynaud L., Borrelli F., Cerini R., Ciampi R., Piazza M., and Borgia G. Hemolytic anemia during pegylated interferon alpha 2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. *Journal of Interferon and Cytokine Research* 2005; 25: 283-285 (I.F. 2017: 2,419).
3. Borgia G., **Gentile I.** Treating chronic hepatitis B: today and tomorrow. *Current Medicinal Chemistry* 2006; 13 : 2839-2855 (I.F. 2017: 3,469).
4. **Gentile I.**, Viola C., Graf, M., Liuzzi R., Quarto M., Cerini R., Piazza M., Borgia G. A Simple Noninvasive Score Predicts Gastroesophageal Varices in Patients With Chronic Viral Hepatitis. *J Clin Gastroenterol* 2009; 43: 81-87 (I.F. 2017: 2,968).
5. Borgia G., **Gentile I.**, Fortunato G., Borrelli F., Borelli S., de Caterina M., Di Taranto M.D., Simone M., Borgia F., Viola C., Reynaud L., Cerini R., Sacchetti L. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. *Liver International* 2009; 29: 248-252 (I.F. 2017: 4,500).
6. **Gentile I.**, Viola C., Paesano L., D'Onofrio M., D'Agostino E., Cerini R., Borrelli F., Piazza M., Borgia G. Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. *J Clin Apher* 2009; 24: 190-196 (I.F. 2017: 2,392).
7. **Gentile I.**, Carleo M.A., Borgia F., Castaldo G., Borgia G. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. *Expert Opin Investig Drugs*. 2010; 19: 151-159 (I.F. 2017: 3,883).
8. **Gentile I.**, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. *Journal of Hepatology* 2010; 52: 778 (I.F. 2017: 14,911).
9. **Gentile I.**, Thabut D. Noninvasive prediction of oesophageal varices: as simple as blood count? *Liver Int.* 2010; 30: 1091-1093 (I.F. 2017: 4,500).
10. Borgia G., Carleo M.A., Gaeta G.B., **Gentile I.** Hepatitis B in pregnancy. *World Journal of Gastroenterology* 2012; 18: 4677- 4683 (I.F. 2017: 3,300).
11. **Gentile I.**, Coppola N, Pasquale N, Liuzzi R, D'Armiento M, Di Lorenzo ME, Capoluongo N, Buonomo AR, Sagnelli E, Morisco F, Caporaso N, Borgia G. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. *Hepatitis Monthly* 2013; 13: e8352 (I.F. 2017: 1,810).
12. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, **Gentile I.**, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. *World J Gastroenterol.* 2013; 19: 2793-8 (I.F. 2017: 3,300).
13. **Gentile I.**, Zappulo E, Militeri R, Pascotto A, Borgia G, Bravaccio C. Etiopathogenesis of autism spectrum disorders: Fitting the pieces of the puzzle together. *Medical Hypotheses* 2013; 81: 26-35 (I.F. 2017: 1.120).
14. De Palma M, Grillo M, Borgia G, Pezzullo L, Lombardi CP, **Gentile I.** Antibiotic prophylaxis and risk of infections in thyroid surgery: results from a national study (UEC—Italian Endocrine Surgery Units Association). *Updates in Surgery* 2013; 65: 213-216.
15. **Gentile I.**, Borgia F, Buonomo AR, Castaldo G, Borgia G. A Novel Promising Therapeutic Option Against Hepatitis C Virus: an Oral Nucleotide NS5B Polymerase

- Inhibitor Sofosbuvir. *Current Medicinal Chemistry* 2013; 20: 3733-3742 (I.F. 2017: 3,469).
16. Coppola N, **Gentile I**, Pasquale G, Buonomo AR, Capoluongo N, D'Armiento M, Borgia G, Sagnelli E. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. *Ann Hepatol.* 2014; 13:20-6. (I.F. 2017: 1,576).
 17. Fusco F, D'Anzeo G, Rossi A, Sciorio C, Buonomo AR, d'Emmanuele di Villa Bianca R, Borgia G, Mirone V, **Gentile I**. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. *Expert Opinion on Pharmacotherapy* 2013; 14: 2533-2544 (I.F. 2017: 3,475).
 18. **Gentile I**, Buonomo AR, Borgia F, Castaldo G, Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. *Expert Opin Investig Drugs.* 2014; 23: 561-71. (I.F. 2017: 3,883).
 19. **Gentile I**, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. *Expert Rev Anti Infect Ther* 2014; 12: 775-82 (I.F: 2017: 3.141).
 20. **Gentile I**, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. *Expert Opin Investig Drugs.* 2014; 23: 1211-23 (I.F. 2017: 3,883).
 21. **Gentile I**, Buonomo AR, Borgia G. Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. *Rev Recent Clin Trials* 2014; 9: 115 – 123.
 22. **Gentile I**, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: towards an HCV-free world? *Expert Rev Anti Infect Ther* 2014; 12: 763-773 (I.F: 2017: 3.141).
 23. **Gentile I**, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of HCV infection. *Therapeutics and Clinical Risk Management* 2014; 10: 493-504 (I.F. 2017: 1,995).
 24. **Gentile I**, Buonomo AR, Zappulo E, Coppola N, Borgia G. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. *Expert Rev Anti Infect Ther* 2014; 12: 10: 1179-1186 (I.F: 2017: 3,141).
 25. **Gentile I**, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. *Expert Rev Anti Infect Ther* 2014; 12:1033-43 (I.F: 2017: 3,141).
 26. **Gentile I**, Borgia G. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. *Evid Based Med* 2014; 19: 223-4
 27. **Gentile I**, Borgia F, Buonomo AR, Zappulo E, Castaldo G, Borgia G. ABT-450: A Novel Protease Inhibitor For the Treatment of Hepatitis C Virus Infection. *Current Medicinal Chemistry* 2014; 21: 3261-70. (I.F. 2017: 3,469).
 28. **Gentile I**, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012-2013: hepatitis C virus infection. *Expert Opinion On Investigational Drugs* 2015; 24: 239-51 (I.F. 2017: 3,883).
 29. Zampino R, Pisaturo MA, Cirillo G, Marrone A, Macera M, Rinaldi L, Stanzone M, Durante-Mangoni E, **Gentile I**, Sagnelli E, Signoriello G, Miraglia Del Giudice E, Adinolfi LE, Coppola N. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. *Annals of Hepatology* 2015; 14:75-82. (I.F.:2017: 1,576).
 30. **Gentile I**, Scarano F, Celotti A, De Iulio E, Scarano R, Granata V, Pinchera B, Meola M, D'Ambra A, Piccirillo M, Di Paola F, Cavalcanti E, Izzo F, Scarpato N, Borgia G. Low Vitamin D Levels Are Associated with the Presence of Serum

- Cryoglobulins in Patients with Chronic HCV Infection. *In Vivo* 2015; 29:399-404. (I.F. 2017: 1,116).
31. **Gentile I**, Borgia G. A pill a day keeps HCV away. *Lancet Infectious Diseases* 2015; 15: 616-617 (I.F. 2017: 25,148).
 32. Borgia G, Maraolo AE, Foggia M, Buonomo AR, **Gentile I**. Fecal microbiota transplantation for *Clostridium difficile* infection: back to the future. *Expert Opinion On Biological Therapy*. 2015;15:1001-14. (I.F. 2017: 3,974).
 33. **Gentile I**, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. *Expert Opin Drug Discov*. 2015;10:1363-77 (I.F. 2017: 4,692).
 34. **Gentile I**, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. *Expert Opin Investig Drugs*. 2016;25:557-72 (I.F. 2017: 3,883).
 35. **Gentile I**, Maraolo AE, Borgia G. What is the role of the new β -lactam/ β -lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? *Expert Rev Anti Infect Ther*. 2016;14:875-8. (I.F. 2017: 3,141).
 36. **Gentile I**, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. *Expert Rev Gastroenterol Hepatol*. 2016;10:1227-1234. (I.F. 2017: 2,963).
 37. Coppola N, Zampino R, Bellini G, Stanzione M, Capoluongo N, Marrone A, Macera M, Adinolfi LE, Giudice EM, **Gentile I**, Sagnelli E, Rossi F. CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. *Dig Liver Dis*. 2016 Nov;48(11):1364-1369. (I.F. 2017: 3,287).
 38. Borgia G, Maraolo AE, **Gentile I**. Hepatitis B mother-to-child transmission and infants immunization: we have not come to the end of the story yet. *Infect Dis (Lond)*. 2017;49:584-587.
 39. **Gentile I**, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, Borgia G. Successful treatment of post-surgical osteomyelitis caused by XDR *Pseudomonas aeruginosa* with ceftolozane/tazobactam monotherapy. *J Antimicrob Chemother*. 2017;72:2678-2679 (I.F. 2017: 5,217).
 40. Fiore M, Maraolo AE, Chiodini P, Cerchione C, **Gentile I**, Borgia G, Pace MC. Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review. *Cardiovasc Hematol Disord Drug Targets*. 2017;17:105-110.
 41. Fiore M, Maraolo AE, **Gentile I**, Borgia G, Leone S, Sansone P, Passavanti MB, Aurilio C, Pace MC. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review. *World J Gastroenterol*. 2017;23:4654-4660. (I.F. 2017: 3,300).
 42. Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, De Rosa FG, **Gentile I**. Management of multidrug-resistant *Pseudomonas aeruginosa* in the intensive care unit: state of the art. *Expert Rev Anti Infect Ther*. 2017;15:861-871. (I.F. 2017: 3,141).
 43. Buonomo AR, Zappulo E, Scotto R, Pinchera B, Perruolo G, Formisano P, Borgia G, **Gentile I**. Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. *Int J Infect Dis*. 2017;63:23-29 (I.F. 2017: 3,202).
 44. **Gentile I**, Buonomo AR, Scotto R, Zappulo E, Borgia G. Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. *Eur J Intern Med*. 2017;46:e45-e47. (I.F. 2017: 3,282).
 45. Fiore M, Maraolo AE, Leone S, **Gentile I**, Cuomo A, Schiavone V, Bimonte S, Pace MC, Cascella M. Spontaneous peritonitis in critically ill cirrhotic patients: a

- diagnostic algorithm for clinicians and future perspectives. *Ther Clin Risk Manag.* 2017;13:1409-1414. (I.F. 2017: 1,995).
46. Buonomo AR, Scotto R, Pinchera B, Coppola N, Monari C, Macera M, Borgia G, **Gentile I**. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. *New Microbiol.* 2018;41:26-29. (I.F. 2017: 1,412)
 47. Papst L, Beović B, Pulcini C, Durante-Mangoni E, Rodríguez-Baño J, Kaye KS, Daikos GL, Raka L, Paul M; ESGAP, ESGBIS, **ESGIE and the CRGNB treatment survey study group**. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infection diseases specialists practicing in large hospitals. *Clin Microbiol Infect.* 2018. pii: S1198-743X(18)30069-7. In press. (I.F. 2017: 5,394).
 48. Fiore M, Cascella M, Bimonte S, Maraolo AE, **Gentile I**, Schiavone V, Pace MC. Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies. *Infect Drug Resist.* 2018;11:177-186. (I.F. 2017: 3,443).
 49. Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, De Rosa FG, **Gentile I**. Response to: 'letter to the editor: "Management of multidrug-resistant *Pseudomonas aeruginosa* in the Intensive Care Unit: State of the art". *Expert Rev Anti Infect Ther.* 2018;16:369-371 (I.F. 2017: 3.141).
 50. Bartoletti M, Giannella M, Lewis R, Caraceni P, Tedeschi S, Paul M, Schramm C, Bruns T, Merli M, Cobos-Trigueros N, Seminari E, Retamar P, Muñoz P, Tumbarello M, Burra P, Torrani Cerenzia M, Barsic B, Calbo E, Maraolo AE, Petrosillo N, Galan-Ladero MA, D'Offizi G, Bar Sinai N, Rodríguez-Baño J, Verucchi G, Bernardi M, Viale P; ESGBIS/BICHROME Study Group. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. *Clin Microbiol Infect.* 2018;24:546.e1-546.e8. (I.F. 2017: 5,394).
 51. Fiore M, **Gentile I**, Maraolo AE, Leone S, Simeon V, Chiodini P, Pace MC, Gustot T, Taccone FS. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. *Eur J Gastroenterol Hepatol.* 2018;30:329-336 (I.F. 2017: 2,014).
 52. Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, **Gentile I**. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. *Expert Opin Drug Saf.* 2018;17:709-717 (I.F. 2017: 3,156).
 53. Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, Gori A, Girardi E, Mussini C, Bonfanti P, Ammassari A, d'Arminio Monforte A; **Icna Foundation Study Group**. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. *BMC Public Health.* 2018;18:870 (I.F. 2017: 2,420).
 54. Maraolo AE, **Gentile I**, Pinchera B, Nappa S, Borgia G. Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. *Expert Opin Pharmacother.* 2018; 19: 1317-1325 (I.F. 2017: 3,475).
 55. **Gentile I**, Fusco F, Buonomo AR, Scotto R, Zappulo E, Pinchera B, Persico F, Califano G, Borgia G, Longo N. Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. *Sex Health.* 2018 Jul 26. In Press (I.F. 2017: 1,246)
 56. Maraolo AE, **Gentile I**, Buonomo AR, Pinchera B, Borgia G. Current evidence on the management of hepatitis B in pregnancy. *World J Hepatol.* 2018;10:585-594.
 57. Maraolo AE, Buonomo AR, Zappulo E, Scotto R, Pinchera B, **Gentile I**. Unsolved issues in the treatment of spontaneous peritonitis in patients with cirrhosis:

- nosocomial versus community-acquired infections and the role of fungi. *Rev Recent Clin Trials*. 2018 Dec 3. (In press)
58. Buonomo AR, Arcopinto M, Scotto R, Zappulo E, Pinchera B, Sanguedolce S, Perruolo G, Formisano P, Cittadini A, Vespasiani Gentilucci U, Borgia G, **Gentile I**. The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. *Clin Res Hepatol Gastroenterol*. 2018 . pii:S2210-7401(18)30214-6.
 59. **Gentile I**, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, De Pascalis S, Martini S, Macera M, Viceconte G, Tosone G, Buonomo AR, Borgia G, Coppola N. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). *Hepatol Int*. 2019 ;13:66-74.
 60. Buonomo AR, Scotto R, Zappulo E, Nerilli M, Pinchera B, Perruolo G, Formisano P, Nappa S, **Gentile I**. Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. *In Vivo*. 2019;33:177-182.
 61. **Gentile I**, Buonomo AR, Coppola C, Staiano L, Amoruso DC, Saturnino MR, Maraolo AE, Portunato F, De Pascalis S, Martini S, Crispo M, Macera M, Pinchera B, Zappulo E, Scotto R, Coppola N. Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. *New Microbiol*. 2019 Apr 29;41
 62. Coppola N, Portunato F, Buonomo AR, Staiano L, Scotto R, Pinchera B, De Pascalis S, Amoruso DC, Martini S, Pisaturo M, Coppola C, **Gentile I**. Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. *J Nephrol*. 2019 Oct;32(5):763-773
 63. **Gentile I**, Pinchera B, Viceconte G, Crispo M, Simeone D, Scotto R, Zappulo E, Maraolo AE, Paladino F, Tortora R, Di Costanzo GG, Buonomo A, Borgia G. Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study. *Infez Med*.; 27) 3 2-39.
 64. Russo CV, Saccà F, Paternoster M, Buonomo AR, **Gentile I**, Scotto R, Brescia Morra V, Mansueto G. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. *Mult Scler*. 2019 18:1352458518813110.
 65. Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A; CEFTABUSE Study Group. Ceftolozane/tazobactam for the treatment of serious *Pseudomonas aeruginosa* infections: a multicentre nationwide clinical experience. *Int J Antimicrob Agents*. 2019;53:408-415.
 66. Buonomo AR, Viceconte G, Compare D, Vargas M, Iacovazzo C, Zappulo E, Nardone G, Servillo G, Borgia G, **Gentile I**. Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease. *IDCases*. 2019;17:e00537.
 67. Di Minno MND, Ambrosino P, Buonomo AR, Pinchera B, Calcaterra I, Crispo M, Scotto R, Borgia F, Mattia C, **Gentile I**. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. *Intern Emerg Med*. 2019 Aug 8. doi: 10.1007/s11739-019-02163-8.
 68. Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, **Gentile I**, Sogari F, Pierri P, Surace LA, Morisco F, Tundo P, Brancaccio G, Serviddio G, Gatti P, Termite AP, Di Costanzo GG, Caroleo B, Cozzolongo R, Coppola N, Longo A,

- Fontanella L, Federico A, Rosato V, Terrenato I, Masarone M. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. *Liver Int.* 2019 Oct;39(10):1852-1859.
69. Corcione S, Lupia T, Maraolo AE, Mornese Pinna S, **Gentile I**, De Rosa FG. Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. *Curr Opin Infect Dis.* 2019 (In Press)

Napoli, 22.10.2019